EMA Guide on Biosimilars for Healthcare Professionals Available Now in 23 Official EU Languages
The guide is updated in October 2019
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The guide is updated in October 2019
Clinical activity observed even in patients with CNS metastases and those previously treated with crizotinib
Higher proportion of serious and fatal adverse drug reactions reported among males
FDA also approved the Myriad myChoice CDx test for determination of tumour HRD status to select patients for niraparib
It is a biosimilar of Neulasta which was authorised in the EU in 2002
Addressing an unmet need to increase ability to study rectal cancer
The increase in incidence of pancreatic cancer is likely to continue as the population ages
It was developed for the treatment of patients with FLT3-ITD positive AML
New indication concerns its combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
New indication concerns mono or combination with chemotherapy in the first-line treatment of metastatic or unresectable recurrent HNSCC
A programme of research into social outcomes after AYA cancer and its treatment
Awarded discoveries paved the way for promising new strategies to fight anaemia, cancer and many other diseases
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.